Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden

INTRODUCTION: A new treatment plan was implemented at Skåne University Hospital, on economic grounds, for children requiring recombinant human growth hormone (rhGH) treatment. This involved switching patients from treatment with originator rhGHs to treatment with a biosimilar rhGH, somatropin (Omnit...

Descripción completa

Detalles Bibliográficos
Autores principales: Flodmark, Carl-Erik, Lilja, Katarina, Woehling, Heike, Järvholm, Kajsa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873057/
https://www.ncbi.nlm.nih.gov/pubmed/24392303
http://dx.doi.org/10.1007/s13554-013-0011-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873057/
https://www.ncbi.nlm.nih.gov/pubmed/24392303
http://dx.doi.org/10.1007/s13554-013-0011-z

Ejemplares similares